Cargando…

Vaccination against COVID‐19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Detalles Bibliográficos
Autores principales:	Kaczmarek, Radoslaw, El Ekiaby, Magdy, Hart, Daniel P., Hermans, Cedric, Makris, Mike, Noone, Declan, O’Mahony, Brian, Page, David, Peyvandi, Flora, Pipe, Steven W., Sannié, Thomas, Schlenkrich, Uwe, Skinner, Mark W., Srivastava, Alok, Bok, Amanda, Pierce, Glenn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014441/ https://www.ncbi.nlm.nih.gov/pubmed/33651911 http://dx.doi.org/10.1111/hae.14271

Ejemplares similares

Evolution of Haemophilia Care in Europe: 10 years of the principles of care
por: Noone, D., et al.
Publicado: (2020)

Issues in assessing products for the treatment of hemophilia – the intersection between efficacy, economics, and ethics
por: Farrugia, Albert, et al.
Publicado: (2015)

Association of factor expression levels with annual bleeding rate in people with haemophilia B
por: Burke, Tom, et al.
Publicado: (2022)

How to discuss gene therapy for haemophilia? A patient and physician perspective
por: Miesbach, Wolfgang, et al.
Publicado: (2019)

Achieving the unimaginable: Health equity in haemophilia
por: Skinner, Mark W., et al.
Publicado: (2019)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia
por: Skinner, MW., et al.
Publicado: (2018)

Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH
por: Konkle, Barbara, et al.
Publicado: (2020)

Evidence of a disability paradox in patient‐reported outcomes in haemophilia
por: O’Hara, Jamie, et al.
Publicado: (2021)

European principles of inhibitor management in patients with haemophilia: implications of new treatment options
por: Hermans, C., et al.
Publicado: (2020)

Management of haemophilia A with inhibitors: A regional cross‐talk
por: Peyvandi, Flora, et al.
Publicado: (2022)

Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study
por: Kennedy, Megan, et al.
Publicado: (2022)

Low‐dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success
por: Elalfy, Mohsen, et al.
Publicado: (2021)

The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): A scoping review
por: Boccalandro, Elena A., et al.
Publicado: (2022)

Burden of mild haemophilia A: Systematic literature review
por: Peyvandi, Flora, et al.
Publicado: (2019)

Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment
por: Witkop, Michelle, et al.
Publicado: (2021)

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies
por: Peyvandi, Flora, et al.
Publicado: (2020)

Cardiovascular disease in hereditary haemophilia: The challenges of longevity
por: Shapiro, Susan, et al.
Publicado: (2022)

Haemophilia gene therapy: experiences and lessons from treated patients
por: Hermans, Cedric
Publicado: (2022)

Pain and pain management in haemophilia
por: Auerswald, Günter, et al.
Publicado: (2016)

Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
por: Spena, Silvia, et al.
Publicado: (2022)

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire
por: Chai-Adisaksopha, Chatree, et al.
Publicado: (2018)

Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A
por: Schmitt, Christophe, et al.
Publicado: (2022)

A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen
por: Kennedy, Megan, et al.
Publicado: (2021)

Hemophilia gene therapy knowledge and perceptions: Results of an international survey
por: Peyvandi, Flora, et al.
Publicado: (2020)

Précautions standard – Précautions complémentaires
por: HALLOUËT, Pascal, et al.
Publicado: (2015)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database
por: Peyvandi, Flora, et al.
Publicado: (2020)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
por: Hassan, Shermarke, et al.
Publicado: (2021)

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments
por: Gouw, Samantha C., et al.
Publicado: (2018)

Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company
por: Hay, Charles R. M., et al.
Publicado: (2020)

Physical activity, physical fitness and cardiometabolic risk amongst adults with moderate and severe haemophilia
por: Kennedy, Megan, et al.
Publicado: (2022)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

The Role of Physiotherapy in the New Treatment Landscape for Haemophilia
por: Lobet, Sébastien, et al.
Publicado: (2021)

Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review
por: Hermans, Cedric, et al.
Publicado: (2020)

Emicizumab in acquired haemophilia A: about two clinical cases and literature review
por: Hansenne, Amandine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kj84ee7vdrklj396jr7eam63hh